Currently Enrolling Studies

To view more information about the studies click the NCT number.

Protocol Number Indication Protocol NCT number
#SAT001 Advanced Solid Tumor A First- in- Human Phase 1 Trial to Determine the Safety and the Pharmackokinetic Profile of a Drug in Patients with Advanced Solid Tumors NCT03416816
#SAT002 Advanced Solid Tumor A Phase 1 Study for Study Participants with BRAFF V-600 Mutation in Melanoma or other Solid Tumors NCT03864042
#BRE001 Breast A Phase 1a/1b Study of an Anti-B7-H4 Antibody, in Patients with Advanced Solid Tumors NCT03514121
BRE002 Breast A Phase 3 Open-Label, Randomized, Study of a Drug Versus Treatment of Physician’s Choice in Patients with Metastatic Breast Cancer who Have Stable Brain Metastases and Have Been Previously Treated NCT02915744
BRE003 Breast A Phase 3, Randomized, Open-Label Trial to Compare the Efficacy and Safety of a Drug with Endocrine Therapy as Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer NCT03701334
BRE004 Breast A multi-centre, double-blind, placebo-controlled, randomized phase II trial to compare efficacy of a drug in post-menopausal women with HR+ / HER2- metastatic breast cancer NCT03659136
#END0001 Endometrial A Phase 1a/1b Study of an Antibody, in Patients with Advanced Solid Tumors NCT03514121
#END0002 Endometrial A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of a drug in Combination with Another Drug Versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer NCT03884101
GAS001 Gastric A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating a Drug in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer NCT03694522
LUN001 Lung NSCLC A Randomized, Double-Blind, Phase 3 Study of Chemotherapy with or without a Drug EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) NCT03515837
LYM001 Lymphoma A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Drug in Patients with Relapsed Indolent B-Cell Non-Hodgkin’s Lymphoma (iNHL). NCT02367040
MDS001 MDS Low Risk A Phase3,Open-Label,Randomized Study to Compare the Efficacy and Safety of a Drug Verses Standard Therapy for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk MDS in ESA Naïve Subjects who Require Red Blood Cell Transfusions NCT03682536
MM001 Multiple Myeloma Multicenter Phase 2 Study injection in Combination with Standard Multiple Myeloma Treatment Regimens NCT03412565
#OVA001 Ovarian A Phase 1a/1b Study of an Antibody, in Patients with Previously Treated Ovarian Cancer NCT03514121
#OVA002 Ovarian A Randomized, Double-Blind, Phase 3 Study Comparison of Platinum-Based Therapy with Two Drugs Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III of IV Nonmucinous Epithelial Ovarian Cancer NCT03602859
PRO001 Prostate A Phase 1b-2 Study of a Drug in Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer NCT03431350
#SAT003 Solid Tumor Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors NA